PRICE T ROWE GROUP INC·4

Jul 1, 10:51 AM ET

MacLellan Robert F. 4

Research Summary

AI-generated summary

Updated

T. Rowe Price (TROW) Director Robert MacLellan Receives Award

What Happened

  • Robert F. MacLellan, a director of T. Rowe Price Group, received equity awards in two entries: 184.553 shares were credited on 2026-06-29 at $114.38 per share (valued at $21,109), and 658 stock units were granted on 2026-06-30 shown with $0.00 cash price (these stock units were issued for director fees — see footnote for per-share valuation).
  • The second grant is accounted at the closing share price of $113.69 on June 30, 2026 (per the filing), which implies the 658 units are worth about $74,808. The 6/29 award reflects dividend reinvestment shares (some fully vested, some to vest later).

Key Details

  • Transaction dates and prices:
    • 2026-06-29: Award of 184.553 shares at $114.38 (acquired) — $21,109 total.
    • 2026-06-30: Award/grant of 658 stock units at $0.00 cash price (issued for director fees); filing values them at $113.69/share.
  • Shares owned after transaction: Not specified in the provided filing information.
  • Footnotes:
    • F1: Awards under the 2017 Non-Employee Director Equity Plan related to dividends — some shares were credited as fully vested dividend reinvestment shares; some will accrue and vest later when the corresponding grant vests.
    • F2: 658 Stock Units issued for Director Fee Awards were priced at $113.69 (closing price) and will vest in full and become nonforfeitable on the grant date.
  • Filing timeliness: Form 4 filed 2026-07-01 for transactions on 2026-06-29/30; no late filing flag indicated in the provided data.

Context

  • These entries are grants/awards (equity compensation for a non-employee director), not open-market purchases or sales — common routine compensation for board service and not a direct market buy/sell signal. The grants include fully vested dividend reinvestment shares and stock units that are nonforfeitable per the plan terms noted in the footnotes.